)
Visual
test
Biosyent
Biosyent (RX) investor relations material
Biosyent Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary20 Nov, 2025
Executive summary
Achieved record Q3 2025 sales of $12.2M, up 28% year-over-year, and YTD sales of $33.4M, up 27% year-over-year.
EBITDA for Q3 2025 was $3.63M (27% growth, 30% margin); YTD EBITDA was $9.59M (35% growth, 29% margin).
Net income after tax for Q3 2025 was $2.7M (16% growth, 22% margin); YTD net income was $7.02M (24% growth, 21% margin).
61 consecutive profitable quarters, with trailing 12-month EPS of $0.75 and Q3 2025 EPS of $0.23, both trending upward.
FeraMAX and Tibella/Tibelia products contributed significantly to profitable sales growth in Canada and internationally.
Financial highlights
Gross profit for Q3 2025 was $9.27M, up 24% year-over-year; YTD gross profit was $25.5M, up 23%.
Trailing twelve months cash from operations was $8.1M; working capital was $28.9M as of September 30, 2025.
Fully diluted EPS for Q3 2025 was $0.23, up 19% year-over-year; YTD EPS was $0.61, up 28%.
Segment performance
Canadian Pharma Q3 2025 sales were $9.9M (+19% YoY); YTD $28.4M (+16% YoY).
International Pharma Q3 2025 sales were $1.2M (+94% YoY); YTD $3.1M (+316% YoY).
Legacy business Q3 2025 sales were $1.2M (+83% YoY); YTD $1.9M (+73% YoY).
FeraMAX, Tabelia/Tibella, and Inofolic brands performed strongly, with Inofolic showing promising growth from a small base.
Combogesic business declined; company to exit this asset at the start of 2026 to reallocate investment.
Criteria for future portfolio investment decisions
Impact of FeraMAX market competition and growth
Capital deployment priorities for M&A and growth
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 543220
Strong revenue and profit growth in Q3 FY26, driven by expansion and digital gains. - AKTIA
Strong Q4, life insurance up 24%, EUR 70.1M impairment, CET1 ratio at 12.6% for year-end. - RÖKO
Net sales and profit rose, margins improved, and three acquisitions and an IPO were completed. - PNDORA
2025 organic growth was 6% with 23.9% EBIT margin; 2026 outlook remains cautious. - MARKSANS
Quarterly revenue and profit rose year-over-year, supported by global expansion and strong cash flow. - NEWA
Record revenue above SEK 10 billion, solid growth, and a SEK 3.00 dividend proposed. - 513023
Quarterly profit surged on strong mining and energy results, despite ongoing receivable risks. - GODREJPROP
Record Q3 FY26 bookings, strong profit growth, and robust margins with one-time labour cost impact. - 507717
Quarterly net profit reached ₹3,999.54 lakhs, with key board and committee changes approved. - MINDACORP
Strong revenue and profit growth, interim dividend, and regulatory impact recognized.
Next Biosyent earnings date
Q4 202516 Mar, 2026
Biosyent
Next Biosyent earnings date
Q4 202516 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada. It focuses on the acquisition of oncology drugs, medical devices and other healthcare products. BioSyent Inc. is based in Mississauga, Canada.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage